Saturday 17 October 2026 Export COCP’s income statement to Excel — free account

Cocrystal Pharma, Inc.

In the quarter to June 2026, revenue fell 81.1%, EPS fell 15.0% and free cash flow fell 16.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.02 0.01 −0.97%

Follow COCP

Alert me

Market cap: $19.8M
P/E: 0.0×
Fwd P/E: −4.1×
Dividend yield: —
F-score: n/a
Altman Z: 19.78
Beneish M: −1.65
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.30

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	2	3	—	2	—	—	—	—	—	2	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 7.09%

Capital & Financial Ratios $m

Market Cap 19.84

Revenue 1.33

Net Income (9.94)

Free Cash Flow (7.95)

Net Debt (2.24)

Current Ratio 1.24

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (4.06)

P/S ratio 10.58

P/B ratio 13.47

Past 5Y EPS Growth —

This Y EPS Growth 7.05%

Next Y EPS Growth 34.48%

Next Y revenue growth (100.00%)

Next 5Y EPS Growth 6.87%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 33.65%

10-year low 10-year high

P/B against its own 10 years 90.93%

10-year low 10-year high

EV/Sales against its own 10 years 33.37%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	26	10	7	2
Receivables	1	1	1	1
Inventory	—	—	—	—
Other	—	—	—	—
	29	12	8	3

	2023	2024	2025	Q'26
Payables	3	2	2	2
ST’ Debt	—	—	—	—
Other	—	—	—	—
	3	2	2	3

Compound Annual Growth %

	10y	5y	3y
Sales	—	(33.30%)	507.12%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(27.94%)	(34.50%)	(45.71%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’20	0	1	0	1	2

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(3)	—	—	—
’25	(3)	(2)	(1)	(2)	(8)
’24	(5)	(4)	(5)	(3)	(16)
’23	(3)	(6)	(3)	(3)	(15)
’22	(4)	(4)	(9)	(5)	(21)
’21	(2)	(3)	(5)	(3)	(13)
’20	(2)	(2)	(3)	(2)	(10)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(3)	—	—	—
’25	(3)	(2)	(1)	(2)	(8)
’24	(5)	(4)	(5)	(3)	(16)
’23	(3)	(6)	(3)	(3)	(15)
’22	(4)	(4)	(9)	(5)	(22)
’21	(2)	(3)	(5)	(3)	(13)
’20	(2)	(2)	(3)	(2)	(10)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.17)	(0.23)	—	—	—
’25	(0.23)	(0.20)	(0.19)	(0.17)	(0.78)
’24	(0.39)	(0.53)	(0.49)	(0.32)	(1.72)
’23	(0.64)	(0.50)	(0.41)	(0.44)	(1.87)
’22	(0.48)	(3.00)	(0.70)	(0.55)	(4.77)
’21	(0.48)	(0.48)	(0.48)	(0.48)	(1.92)
’20	(0.60)	(0.84)	(0.60)	(0.12)	(2.04)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	115.20	57.60	18.12	4.68	5.40	7.68	1.74	1.38	1.33	0.90	Analyst estimates 2026–2028 Powerpack
	High	331.20	147.60	82.80	63.36	36.48	41.52	8.88	3.29	3.26	2.67
People
People	Employees	18	10	10	11	13	13	12	12	11	10
	Revenue/emp, $m	0.00	0.00	0.00	0.60	0.15	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	7	2	—	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	100.00	100.00	0.00	0.00	—	—	—
	EBT	(104)	(7)	(63)	(48)	(10)	(14)	(39)	(18)	(18)	(9)
	EBT margin, %	0.00	0.00	0.00	(733.84)	(479.05)	0.00	0.00	0.00	0.00	0.00
	Net income	(75)	(1)	(49)	(48)	(10)	(14)	(39)	(18)	(18)	(9)
	Depreciation	0	0	0	46	0	0	19	(1)	0	0
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	2.47	0.44	0.00	0.00	0.00	0.00	0.00
	Earnings	(38.22)	(0.36)	(20.63)	(18.13)	(2.04)	(1.92)	(4.77)	(1.87)	(1.72)	(0.78)
	Cash flow	(7.48)	(3.43)	(3.55)	(0.59)	(2.14)	(1.73)	(2.63)	(1.52)	(1.62)	(0.73)
	Capex	(0.03)	(0.02)	(0.01)	(0.05)	(0.05)	(0.01)	(0.01)	(0.01)	0.00	0.00
	Free cash flow	(7.51)	(3.45)	(3.57)	(0.64)	(2.19)	(1.73)	(2.64)	(1.53)	(1.62)	(0.73)
	Book value	52.23	52.45	28.67	9.69	11.42	10.53	4.86	2.73	0.94	0.56
	Shares, m	2	2	2	3	5	7	8	10	10	11
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	—	—	—	—	—
	P/S	—	—	—	2.43	37.27	—	—	—	—	—
	P/B	—	—	—	0.62	1.43	—	—	—	—	—
	EV/Sales	—	—	—	1.29	20.87	—	—	—	—	—
	EV/FCF	—	—	—	(4.96)	(4.17)	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(15)	(7)	(8)	(2)	(10)	(13)	(21)	(15)	(16)	(8)
	Capex	0	0	0	0	0	0	0	0	0	0
	Free cash flow	(15)	(7)	(8)	(2)	(10)	(13)	(22)	(15)	(16)	(8)
Balance, $m
Balance, $m	Working capital	3	1	1	6	33	58	39	26	9	6
	Total debt	—	1	0	0	0	0	0	—	—	—
	Net debt	(4)	0	(3)	(7)	(33)	(59)	(37)	(26)	(10)	(7)
	Shareholders’ equity	102	105	67	26	53	78	40	26	10	6
Returns, %
Returns, %	ROA	(42.89)	(0.50)	(51.63)	(99.22)	(23.31)	(21.23)	(64.60)	(49.89)	(78.29)	(76.23)
	ROIC	(67.02)	(4.89)	(61.21)	(165.74)	(30.76)	(47.27)	(1,033.57)	0.00	0.00	0.00
	ROE	(55.48)	(0.59)	(56.94)	(104.04)	(24.67)	(21.81)	(66.32)	(54.54)	(97.50)	(111.40)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2020 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CNTX Context Therapeutics Inc.	$22.1M	— (loss-making)	—	—	n/m	−20.61% (below 0%: shrinking)	0.00%	0.00%	Compare
QNTM Quantum Biopharma Ltd.	$21.9M	— (loss-making)	— (loss-making)	—	n/m	+5.88% (above 0%: growing)	0.00%	0.00%	Compare
KYNB Kyntra Bio Inc	$21.7M	0.1×	— (loss-making)	−209.35% (below 0%: shrinking)	n/m	−131.50% (below 0%: shrinking)	100.14%	1,192.27%	Compare
COCP Cocrystal Pharma, Inc.	$19.8M	— (loss-making)	— (loss-making)	−81.05% (below 0%: shrinking)	n/m	−16.75% (below 0%: shrinking)	100.00%	(3,032.38%)
ATYR aTyr Pharma, Inc.	$18.0M	— (loss-making)	— (loss-making)	−90.75% (below 0%: shrinking)	n/m	+32.22% (above 0%: growing)	100.00%	0.00%	Compare
NEUP Neuphoria Therapeutics Inc.	$17.9M	— (loss-making)	— (loss-making)	−107.32% (below 0%: shrinking)	n/m	+133.86% (above 0%: growing)	100.00%	0.00%	Compare
JSPR Jasper Therapeutics, Inc.	$17.7M	— (loss-making)	—	—	n/m	+55.74% (above 0%: growing)	0.00%	0.00%	Compare
ANEB Anebulo Pharmaceuticals, Inc.	$17.6M	— (loss-making)	—	—	n/m	+6.58% (above 0%: growing)	—	0.00%	Compare
ACGN Aceragen, Inc.	$17.1M	— (loss-making)	— (loss-making)	+2,394.95% (above 0%: growing)	n/m	−115.67% (below 0%: shrinking)	100.00%	(834.33%)	Compare
Median of peers	$18.0M	—	—	−99.03%	—	+6.23%	100.00%	0.00%

All 614 Biotechnology stocks →

Cocrystal Pharma, Inc. (COCP) key facts

Cocrystal Pharma, Inc. (COCP) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, COCP traded at $1.02, a market capitalization of $19.8 million.
Return on equity was −111.4% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.